FDA Approves Pfizer’s XALKORI® For Lung Cancer Patients Local or Metastatic Non-Small Therapy-Will It Affordable?
Posted Aug 26 2011 7:35pm
This is the first drug in 6 years to treat lung cancer but we seem to have a trend lately of the drugs being very expensive and not to mention the current shortage of generic drugs that treat cancer. A quick search of the internet says the cost will be $9600 a month so again that runs into some money pretty quickly. Now that we know the cost, please read the link below on how a new “scoring” algorithm has been developed to tell people how long they have to live…keep an eye out on this as we hope it will not be used to determine who gets care and who does not. Actually the link below discusses how formulas are being used both constructively and the potential for abuse so read up as everyone is combining data from all different types of sources today and we have ethics issues forming rapidly. BD
NEW YORK--( BUSINESS WIRE )--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI® (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test. The effectiveness of XALKORI is based on objective response rates (ORR) and, as XALKORI received accelerated approval from the FDA, Pfizer is conducting post-marketing clinical trials to further evaluate its clinical benefit.
“The development of XALKORI – from publication of the discovery of the ALK fusion gene in NSCLC to FDA approval in just four years - is a remarkable feat in the oncology world and reinforces the importance of collaboration among academic research, pharmaceutical, diagnostic and regulatory organizations.”
“Overall, lung cancer is responsible for more deaths each year worldwide than any other type of cancer. XALKORI is an advance in the treatment of this devastating illness, providing a new therapeutic option for a subset of patients with the disease,” said Ian Read, president and chief executive officer of Pfizer. “The acceleration, collaboration and critical focus of the XALKORI clinical development program reflect Pfizer’s Precision Medicine approach to advancing our pipeline and strengthening our innovative core to deliver medicines that matter most.”